Philippe D, Favre L, Foata F, Adolfsson O, Perruisseau-Carrier G, Vidal K, Reuteler G, Dayer-Schneider J, Mueller C, Blum S. Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis. World J Gastroenterol 2011; 17(4): 459-469
Corresponding Author of This Article
David Philippe, PhD, Department of Nutrition and Health, Nestlé Research Centre, Vers-chez-les-Blanc, PO Box 44, CH-1000 Lausanne 26, Switzerland. firstname.lastname@example.org
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 28, 2011; 17(4): 459-469 Published online Jan 28, 2011. doi: 10.3748/WJG.v17.i4.459
Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis
David Philippe, Laurent Favre, Francis Foata, Oskar Adolfsson, Genevieve Perruisseau-Carrier, Karine Vidal, Gloria Reuteler, Johanna Dayer-Schneider, Christoph Mueller, Stéphanie Blum
David Philippe, Laurent Favre, Francis Foata, Oskar Adolfsson, Genevieve Perruisseau-Carrier, Karine Vidal, Gloria Reuteler, Stéphanie Blum, Department of Nutrition and Health, Nestlé Research Centre, CH-1000 Lausanne 26, Switzerland
Johanna Dayer-Schneider, Christoph Mueller, Department of Pathology, University of Bern, CH-3010 Bern, Switzerland
Author contributions: Philippe D and Favre L wrote the manuscript and contributed equally to this work; Philippe D, Favre L, Adolfsson O, Vidal K, Mueller C, Foata F and Blum S designed the study and participated in data analysis; Foata F, Perruisseau-Carrier G, Dayer-Schneider J and Reuteler G performed research; all authors approved the final manuscript.
Correspondence to: David Philippe, PhD, Department of Nutrition and Health, Nestlé Research Centre, Vers-chez-les-Blanc, PO Box 44, CH-1000 Lausanne 26, Switzerland. email@example.com
Telephone: +41-21-7858967 Fax: +41-21-7858544
Received: July 8, 2010 Revised: July 30, 2010 Accepted: August 7, 2010 Published online: January 28, 2011
AIM: To assess the anti-inflammatory effect of the probiotic Bifidobacterium lactis (B. lactis) in an adoptive transfer model of colitis.
METHODS: Donor and recipient mice received either B. lactis or bacterial culture medium as control (deMan Rogosa Sharpe) in drinking water for one week prior to transfer of a mix of naive and regulatory T cells until sacrifice.
RESULTS: All recipient mice developed signs of colonic inflammation, but a significant reduction of weight loss was observed in B. lactis-fed recipient mice compared to control mice. Moreover, a trend toward a diminution of mucosal thickness and attenuated epithelial damage was revealed. Colonic expression of pro-inflammatory and T cell markers was significantly reduced in B. lactis-fed recipient mice compared to controls. Concomitantly, forkhead box protein 3, a marker of regulatory T cells, was significantly up-regulated by B. lactis.
CONCLUSION: Daily oral administration of B. lactis was able to reduce inflammatory and T cells mediators and to promote regulatory T cells specific markers in a mouse model of colitis.
Citation: Philippe D, Favre L, Foata F, Adolfsson O, Perruisseau-Carrier G, Vidal K, Reuteler G, Dayer-Schneider J, Mueller C, Blum S. Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis. World J Gastroenterol 2011; 17(4): 459-469
Crohn’s disease (CD) and ulcerative colitis (UC), referred to as inflammatory bowel diseases (IBDs), are chronic relapsing and remitting inflammatory diseases of the gastrointestinal tract. IBD affects people in the prime of their lives, with first diagnosis usually between the ages of 15 and 25 years, and due to the chronic nature of IBD, patients usually require lifelong treatment. More than one million people in the United States and more than four million people worldwide suffer from IBD. According to the current increase in affected people, IBD medical costs will reach approximately 2 billion euros by the end of 2010. The high cost and limited response to current therapies prompt research and development of new treatment options.
IBD is thought to result from an inappropriate, overwhelming and ongoing activation of the mucosal immune system in genetically susceptible individuals driven by antigens originating from the microbiota of the gastrointestinal tract. Some of the immune-related characteristics of IBD include over-activity of effector lymphocytes, induction of pro-inflammatory cytokines, and failure of regulatory T cells (Tregs) to control inflammation[2,3].
The crucial role of the intestinal microbiota in the induction and progress of disease has been validated in patients and in animal models of intestinal inflammation resembling IBD[4,5]. Indeed, it was demonstrated that intestinal inflammation could not be induced under germ-free conditions and that antibiotic treatment attenuated the disease severity. Interestingly, the equilibrium of the intestinal microbiota appears to be perturbed in IBD as decreased levels of Bifidobacterium and Lactobacillus strains have been described in fecal samples, whereas raised counts of Enterococcus and Bacteroides species are found in inflamed mucosa of patients. Thus, as probiotics are known to have a strong homeostatic impact on the intestinal flora, it is valuable to consider probiotics as alternative therapies for IBD. Hence, although conflicting reports exist, a number of studies report the benefits of probiotic therapy in the alleviation of IBD[10-13]. For example, VSL#3, a mixture of four lactobacilli, three bifidobacteria and a streptococcus species, proved to be effective in inducing and maintaining remission in UC patients or in preventing pouchitis[14-17].
While most clinical studies have relied on mixes of probiotic strains or on synbiotics to act on IBD, a few preclinical or ex-vivo studies have begun to reveal that the use of single probiotic strains, mainly consisting of Lactobacillus strains, can also be efficient in dampening inflammation[18-21].
The present study reports on the beneficial effects of the use of a single Bifidobacterium strain, Bifidobacterium lactis (B. lactis), on intestinal inflammation in a murine model of T cell-mediated colitis. This well established Th1-type cytokine-mediated hyper-response model relies on the adoptive transfer of CD4+CD45RBhigh naive T cells in immunodeficient mice, such as RAG2-/- mice which lack adaptive immunity. This cell transfer initiates colitis pathology akin to that of humans, which develops as a result of the absence of suppressive regulatory cells in the recipient mice. Indeed, co-transfer of mature CD4+CD45RBlow T cells, a source of Tregs, reduces or even prevents colitis. In the present work, naive T cells were adoptively transferred together with a low proportion of Tregs. This particular setting, still permitting the induction of inflammation in recipient mice, provided an interesting tool allowing the simultaneous analysis of the impact of prophylactic B. lactis administration on both T cell partners involved in the induction (naive T cells) or regulation (Tregs) of IBD pathology.
MATERIALS AND METHODS
C57BL/6J mice (8- to 12-wk-old) were purchased from Harlan (Oxon, UK). Immunodeficient RAG2-/- mice (8- to 12-wk-old) were used from a colony of RAG2-/- mice maintained at the Institute for Labortierkunde, University of Zurich, Switzerland. The RAG2-/- mouse colony was derived from a colony from Bern (Switzerland) by embryo transfer under gnotobiotic conditions and recolonized with an Altered Schaedler Flora.
Preparation of B. lactis and experimental design
A freshly prepared solution containing Bifidobacteria lactis (B. animalis subsp. lactis NCC 2818) from the Nestlé Culture Collection (Nestlé Research Center, Lausanne, Switzerland) was used for this study. This strain was chosen according to in vitro anti-inflammatory properties (data not shown). Bacteria were grown for two passages under strictly anaerobic conditions in deMan Rogosa Sharpe (MRS) broth containing 0.05% cysteine (BD, Switzerland). After quantification of bacteria by serial dilution as described for fecal microbiota, 10% glycerol was added to the bacteria stock; aliquots were made and stored at -80°C until use. Frozen bacteria were added to drinking water each day of the study at 1 × 109 colony-forming units (CFU)/mL leading to a dose approximating 3 × 109 CFU/d per mouse. Donor and recipient mice were supplemented with either probiotic or MRS control solution (both containing 10% glycerol) according the study design (Figure 1). Note that as the settings of the present adoptive transfer model permit a focus on Tregs, probiotics were also given to donor mice in order to potentially stimulate these cells as soon as possible. Each group of recipient mice consisted of 5 mice.
Figure 1 Experimental set up.
Feeding of Bifidobacterium lactis (B. lactis)-fed donors and recipients mice were started on day -7 (D-7) until D0 for donor mice and until D27 for recipients. At D0, donor mice were sacrificed and cell transfer was performed in RAG-/- recipient mice..
Induction of colitis in RAG2-/- mice by adoptive transfer
CD4+ T cells from mesenteric lymph nodes (MLNs) were isolated from C57BL/6 donor mice by negative depletion using MACS technology (Miltenyi Biotec, Germany). The negative fraction, enriched for CD4+ T cells, was stained using Fluorescein isothiocyanate-conjugated CD45RB antibody (mAb) (eBioscience, San Diego, USA) and Phycoerythrin-conjugated CD4 mAb (eBioscience, San Diego, USA). Subsequently, CD4+ T cells were sorted according to the expression of CD45RB on a FACS Aria (BD; Allschwil, Switzerland). Sorted CD4+CD45RBhigh and CD4+CD45RBlow T cells were washed, resuspended at 1 × 106 cells/mL in sterile phosphate buffered saline and injected i.p. at the ratio of 9:1 respectively (2 × 105 total cells) into each of the 8- to12-wk-old syngeneic RAG2-/- recipient mice. This 9:1 ratio was chosen because it still allowed development of colitis despite the co-injection of regulatory cells. Body weight of recipient mice was measured every three days from day 0 to day 21, and then every other day until sacrifice (day 27). Body weights were recorded as percentage of initial body weight.
Fresh fecal samples (approximately 0.05 g) were collected at three time-points during the study: before initiation of B. lactis supplementation (day -7), at the day of T cell transfer (day 0), and at the end of the study (day 27). They were collected into 0.5 mL Ringer’s solution, immediately homogenized and snap-frozen, then stored at -80°C until analysis. Blood samples were collected at the same time points as fecal samples and frozen at -80°C until needed. At the end of the experimental period, mice were sacrificed and colon was divided into three parts. The proximal and the distal parts were snap-frozen in liquid nitrogen for protein and mRNA expression analysis, respectively. A smaller sample of the middle colon was used for histopathological analysis.
Fecal extracts were diluted in pre-reduced Ringer’s solution (0.5% cysteine) to perform serial dilutions (10-2 to 10-6) and then plated. Portions (100 μL) of appropriate dilutions were plated onto selective or semi/selective media. Bifidobacteria were counted on tomato juice agar medium. Plates for the enumeration of Bifidobacteria colonies were incubated at 37°C in anaerobic conditions, in a jar containing Anaerocult A tablets (Merck, Germany), for 48 h. After incubation, each plate was examined for bacterial colonies. The detection-limit for the assessed bacteria dilutions was 103. Bacterial counts were expressed as means log10 CFU/g feces ± SE. Detection of B. lactis was performed by polymerase chain reaction (PCR) using B. lactis-specific primers.
Paraffin-embedded colonic tissue sections were scored as previously described, with minor modifications. Briefly, specimens of the transverse colon of each animal were collected and fixed immediately in 4% buffered paraformaldehyde for 16-24 h for subsequent preparation of paraffin-embedded tissue blocks. Tissue sections were stained with hematoxylin/eosin for subsequent histopathological assessment. Each tissue section was independently evaluated by at least two trained pathologists according to a standard evaluation sheet in a blinded fashion. Histological assessment was performed using the scoring criteria displayed in Table 1. The range of histopathological scores was from 1 (no alteration) to 16 (most severe signs of colitis).
Table 1 Summary of assessed criteria to determine histological scoring.
Infiltration of the colonic lamina propria
Loss of goblet cells
Thickness of the colonic mucosa
Protein extraction and quantification: Colons were homogenized in RIPA (Radio Immuno-Precipitation Assay) buffer containing 50 mmol/L Tris base 50, 150 mmol/L NaCl, 2 mmol/L EDTA (Ethylene Diamine Tetraacetic Acid), 2 mmol/L EGTA (Ethylene Glycol Tetraacetic Acid), 0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS (Sodium Dodecyl Sulfate), 50 mmol/L NaF, 200 μmol/L Na3VO4, 0.1% β-mercaptoethanol, 500 μmol/L AEBSF [4-(2-AminoEthyl) BenzeneSulfonyl Fluoride hydrochloride], 20 μmol/L bestatin, 7 μmol/L E-64, 11 μmol/L leupeptin, 7.5 μmol/L pepstatin A, and 0.4 μmol/L aprotinin. The pH was adjusted to 7.2. The homogenate was then centrifuged at 10 000 g for 10 min at 4°C to remove debris. Protein determination was carried out using a modified Lowry method, as described by the manufacturer (Bio-Rad, USA).
Enzyme-linked immunosorbent assay measurements: Interleukin (IL)-6 and tumor necrosis factor (TNF)-α levels were measured in the colon protein extracts by enzyme-linked immunosorbent assay (ELISA) following the manufacturer’s instructions (R&D Systems, England). To avoid interference of the protein lysis buffer with the ELISA reaction, four independent dilutions were performed. All samples were measured in technical duplicates and the concentration calculations were derived from appropriate standard curves.
Electrophoresis and Western blotting: 50 μg of protein were separated by electrophoresis on a MOPS [3-(N-MorphOlino)PropaneSulfonic acid] SDS running 4%-12% bis-tris gel (Invitrogen, USA). Proteins were then transferred to a nitrocellulose (NC) membrane by electroblotting (30 V for 60 min). Western blot analysis was performed with antibodies against murine cyclooxygenase 2 (COX-2) (Cayman Chemicals, USA), p38 and phospho p38 (Cell Signaling Technology, USA), signal transducer and activator of transcription 3 (STAT-3) and phospho STAT-3 (Cell Signaling Technology, USA) and β-actin (Sigma, St. Louis, MO, USA). Secondary antibodies were from Molecular Probes (USA) or Jackson ImmunoResearch Laboratories (USA). Relative quantitation of bands was determined using the Scion Image Densitometry System (Scion Corp., USA), with all quantities normalized to expression levels of β-actin.
Immunohistochemistry for Ki-67 on formalin-fixed tissue sections: After dewaxing, tissue sections were pretreated in 10 mmol/L citrate buffer, pH 6.0, for 7 min at 1 bar/121°C. Pretreated tissue sections were subsequently incubated for 60 min with a primary rat-anti-mouse Ki-67 mAb (Clone: Tec-3; isotype: rat IgG2a; DakoCytomation, USA). After washing, sections were incubated with the biotinylated secondary reagent (rabbit-anti-rat Ig; absorbed with mouse Ig (DakoCytomation). Streptavidin-HRP complexes with 3,3’-diaminobenzidine as the chromogen were used for detection.
RNA extraction of the homogenized tissues was performed using the NucleoSpin RNA II Kit (Macherey-Nagel, Germany). Total RNA was quantified using the Ribogreen RNA Quantitation Kit (Molecular Probes, USA), and the RNA quality was assessed by Agilent RNA 6000 Nano LabChip Kit (Agilent Technologies, USA). Total RNA (2 μg) was reverse transcribed using Multiscribe reverse transcriptase (Applied Biosystems, USA). Real-time PCR was carried out using custom design Low Density Array (Applied Biosystems, X, USA). The quantitative PCR (qPCR) reactions were performed with 2 ng of cDNA on ABI PRISM 7900HT qPCR machine (Applied Biosystems, USA) piloted by SDS 2.2 software (Applied Biosystems, USA). Results of target mRNA are expressed as the number of specific copies for 106 GAPDH mRNA molecules in the same sample.
Statistical analysis was performed using the two-tailed Mann-Whitney U test. Differences were considered statistically significant when P < 0.05. All data are shown as median ± interquartile-range (IQR) except for the body weight analysis.
Detection of B. lactis in fecal samples
In order to control the probiotic intake, detection of B. lactis in fecal samples was performed using PCR detection. No B. lactis was identified in the feces prior to administration of this strain in donor C57BL/6J and recipient RAG-/- mice. All donor animals receiving the treatment were positive for B. lactis on the day of cell transfer (day 0, data not shown). In the recipient animals, supplemented with the probiotic strain, approximately 1 × 108 CFU of B. Lactis/g fecal content could be measured at day 0 and day 27 (sacrifice day).
Effect of B. lactis on body weight loss
As already described in other studies[29,30], control recipients of CD4+ T cells started to lose body weight from day 9 after adoptive cell transfer. Thereafter they continuously lost weight and on the day of sacrifice (day 27), their body weight was lower than on the day of initial T cell transfer (Figure 2). In contrast, B. lactis-fed recipient mice showed a marked delay of onset of body weight loss, starting only at day 18. Thereafter B. lactis-fed recipients also continued to lose weight until the day of sacrifice (day 27). At the end of the experimental period, body weight of B. lactis-fed recipients of CD4 T cells was comparable to the initial body weight at the time of colitis induction by adoptive T cell transfer (Figure 2).
Figure 2 Bifidobacterium lactis feeding significantly delayed weight loss.
Weight curves for control-fed and Bifidobacterium lactis (B. lactis)-fed recipient mice following adoptive T cell transfer. Every three days or every other day following T cell transfer, body weight (BW) of control-fed and B. lactis-fed recipient mice was recorded. Results are expressed as the mean ± SE (n = 5 mice per group) and statistical significance is indicated (aP < 0.05).
Effect of B. lactis on colon histopathology
Histopathology scores, ranging from 0 (no colitis) to 16 (most severe colitis) (Table 1), were based on the analysis of 6 criteria as described in the methodology section. At sacrifice, the total colitis scores of B. lactis-treated and -untreated recipient groups were not significantly different (data not shown). When each of the histopathology criteria was assessed individually, differences between the two groups of recipients were nonetheless observed at the level of mucosal thickness; B. lactis-treated recipient mice showing a tendency for an attenuated mucosal thickening compared to control recipient mice (Figure 3B), resulting in a lower colitis score as shown in Figure 3A.
Figure 3 Histological assessment of colon inflammation for control- and Bifidobacterium lactis-fed recipient mice following adoptive T cell transfer.
A: Mucosal thickness was assessed using a specific scored graduated from 0-3. Results are expressed as the mean ± interquartile-range (IQR) (n = 5 mice per group); B: Assessment by immunostaining of the proliferation marker Ki67 (proliferating cells are characterised by the brown nuclear staining). Representative examples of longitudinal slices from colons of control colitic (left panel) and Bifidobacterium lactis (B. lactis)-fed colitic (right panel) mice are shown; C: Expression of cyclooxygenase 2 (COX-2) protein in colon tissue samples from colitic mice was quantified by Western blotting analysis (left panel). Individual expressions and relative densitometric quantification of the bands are presented (right panel). Results are expressed as the mean ± IQR (n = 5 mice per group) and statistical significances is indicated.
Beyond criteria used for histopathology scoring, epithelial proliferation is considered to be strongly associated with a gastrointestinal inflammatory status. In order to evaluate these criteria, paraffin-embedded colon sections were stained for Ki67 expression by immunohistochemical labeling reaction to determine the proportion of proliferating cells in the colonic epithelium in colitic mice, treated or not with B. lactis (Figure 3B). Colonic epithelium from all recipient mice showed a high proliferation rate in the lower two-thirds of the colonic crypts (Figure 3B), whereas proliferation was only restricted to crypts in healthy controls (data not shown). Nevertheless, epithelial hyper-proliferation appeared markedly reduced in B. lactis-treated recipient mice (Figure 3B).
Effect of B. lactis on colonic pro-inflammatory markers
The effect of B. lactis feeding on the expression of well known proinflammatory markers, such as COX-2, IL-6 or TNF-α, in the colon of recipient mice was assessed. COX-2 is an enzyme known to be strongly induced in intestinal epithelial cells upon inflammatory conditions. Upon disease induction and in absence of treatment (control recipient group), the protein expression of COX-2 was strongly detected in two out of five samples and slightly in a third one (Figure 3C). Conversely, in the B. lactis-fed group, only one out of five samples had slight COX-2 protein expression (Figure 3C). Relative densitometric quantification of the bands clearly revealed a significant decrease of COX-2 expression in the B. lactis-fed group compared to control mice (Figure 3C).
Feeding with B. lactis also resulted in a significant decrease of IL-6 and TNF-α protein production in the colon of recipient mice compared to the non-treated recipient mice (Figure 4A and C). Accordingly, phosphorylation of the transcription factors STAT-3 and p38, associated with the signaling pathways of these two cytokines, was also diminished by B. lactis feeding (Figure 4B and D).
Figure 4 Bifidobacterium lactis feeding significantly diminished protein expression and phosphorylation status of pro-inflammatory markers in colon of recipient mice following adoptive T cell transfer.
Expression of interleukin-6 (IL-6) (A) and tumor necrosis factor-α (TNF-α) (C) protein was measured by enzyme-linked immunosorbent assay in colon tissue samples from colitic recipients. The ratios of phosphorylated signal transducer and activator of transcription-3 (pSTAT-3) vs STAT-3 (B) and of pp38 vs p38 (D) were assessed by Western blotting analysis in colon tissue samples of colitic mice. Relative densitometric quantifications of the Western blotting bands are presented. Results are expressed as the mean ± interquartile-range (A and C, n = 5; B, n = 3; and D, n = 4 mice per group) and statistical significance is indicated. B. lactis: Bifidobacterium lactis.
Effect of B. lactis on dendritic cell markers
It is now well established that co-stimulatory interactions between antigen-presenting cells and cells of the adaptive immune system, such as the CD40/CD40 ligand (CD40L) and OX40/OX40 ligand (OX40L) (CD134/C134L) pathways, play a crucial role in colitis induction and severity of disease[32,33]. mRNA expressions of these four molecules were thus assessed in colon tissue samples of recipient mice. Whereas they were all induced in recipient mice in comparison to healthy controls (Figure 5A-D), B. lactis feeding significantly down-regulated the expression levels of CD40L and OX40/OX40L when compared to non-treated colitic controls (Figure 5B-D). Expression of CD40 only showed a tendency to be down-regulated by B. lactis feeding.
Figure 5 Bifidobacterium lactis feeding diminished the expression of mRNA coding for antigen-presenting cells and T cell costimulatory molecules in colon of recipient mice following adoptive T cell transfer.
The expressions of mRNA coding for CD40 (A), CD40 ligand (CD40L) (B), OX40 (C) and OX40 ligand (OX40L) (D) were assessed in colon samples of colitic and healthy mice by real-time polymerase chain reaction using the low density array technology. Results are expressed as the mean ± interquartile-range (n = 5 mice per group) and statistical significance is indicated. B. lactis: Bifidobacterium lactis.
Effect of B. lactis on colonic T cell markers
Colitis induction in the transfer model of colitis critically depends on the expansion and preferential differentiation of transferred T cells into Th1 T cells. Hence, T cell-related gene transcripts interferon (IFN)-γ, CD3γ and T-bet were measured in colonic tissue samples in both groups of recipients. All of these T-cell transcripts, highly expressed in colitic animals when compared to healthy control mice, were significantly decreased in B. lactis-fed mice (Figure 6A-C). In order to gain insight into regulatory functions of T cells, mRNA expression of forkhead box protein 3 (Foxp3) in colon samples was also quantified and showed that Treg cells were significantly potentiated by feeding with the probiotics, as a 9.2-fold increase of the expression of Foxp3 was observed in B. lactis-fed mice when compared to control colitic mice (Figure 6D).
Figure 6 Bifidobacterium lactis feeding significantly diminished mRNA expression of Th1 cell markers and significantly increased mRNA expression of a Treg marker in colon of recipient mice following adoptive T cell transfer.
The expressions of mRNA coding for interferon-γ (IFN-γ) (A), CD3γ (B), T-bet (C) and FoxP3 (D) were assessed in colon samples of recipient mice by real-time polymerase chain reaction using the low density array technology. Results are expressed as the mean ± interquartile-range (n = 5 mice per group) and statistical significance is indicated. B. lactis: Bifidobacterium lactis.
The exact etiology of chronic IBD is still unknown but seems complex and multifactorial. From human studies and animal models of experimental colitis, increasing evidence has been generated that the resident intestinal flora play a critical role in the development of the intestinal inflammation in genetically susceptible individuals. Indeed, on given genetic backgrounds, such as in IL-2- and IL-10-knockout mice or in HLA-B27 transgenic rats, as well as in the present colitis model, colitis develops when animals are raised under specific pathogen-free conditions, but almost no disease can be observed under germ-free conditions[34-36]. With regard to the importance of the quality of the microflora in colitis, clinical and preclinical observations have demonstrated beneficial effects of probiotic microorganisms in the treatment of IBD in humans[11,12,14,15] and in experimental models of colitis[20,37-39].
While most reports in the literature describe effects of mixes of probiotic strains or of synbiotics, only a few papers have investigated the beneficial potential of the use of single probiotic strains, and moreover of Bifidobacterium probiotic strains, to alleviate intestinal inflammation. As a preclinical model of IBD, the CD4+CD45RBhigh naive T cell transfer model of colitis[29,30] was exploited in this study. This widely used model of colitis allows the study of the Th1 cell-mediated immune events leading, without treatment, to an irreversible colonic inflammation characterized by a massive influx of mononuclear cells into the colonic mucosa, an elevated level of pro-inflammatory cytokines, appearance of crypt abscesses and epithelial cell erosions. Noteworthy, as for experimental models using genetically modified animals, the composition of the intestinal flora is also clearly known to affect the kinetics and the severity of the colitis in this particular model. Moreover, in the present study, the fact that CD4+CD45RBlow T cells were also transferred to recipient mice permitted us to also study the role that Tregs play in suppressing or limiting the onset and/or regulation of inflammation. Thus, for all the above mentioned reasons, this is to our knowledge one of the few studies that shows the preventive effects of a Bifidobacterium strain on the development of IBD in the CD4+CD45RBhigh T cell reconstituted RAG-2 deficient mouse model with insights on Tregs.
Hence, it was demonstrated in the present study that B. lactis actually possesses in vivo immuno-modulatory properties and was able to improve the inflammatory status of treated mice. Indeed, it was revealed that supplementation of mice with B. lactis, one week before and during onset of colitis, resulted in a diminished colitis-induced weight loss (Figure 2), a reduction of mucosal thickness (Figure 3), a decreased expression of pro-inflammatory cytokines and related transcription factors (Figure 4), a diminution of T cell infiltration (Figure 5) and an increase of regulatory T cell markers (Figure 6) when compared to non-supplemented control animals.
Follow-up analysis of the weight of mice showed that B. lactis treatment significantly delayed the body weight loss observed in control recipient mice (Figure 2), revealing a major impact of the B. lactis supplementation on the overall metabolism of treated mice. After some gain of weight due to normal growth of the mice, weight loss was already visible at day 9 in the control recipient mice whereas this only started at day 18 in the B. lactis-fed mice. In this latter group, no real weight loss was even observed at the end of the study, the mice having reached their starting weight. Whether this weight loss would continue under the starting weight should be tested in future studies.
Concerning histopathological analyses of the colons at sacrifice, even if the benefit observed regarding weight loss was not visible on total score, among all criteria investigated mucosal thickness was particularly improved by probiotic supplementation, suggesting a diminution of cellular infiltration in the mucosa (Figure 3A).
In line with this reduction of colonic thickness, a strong decrease of the reparative proliferative activity of colonic epithelial cells, assessed by immunostaining using the proliferative marker Ki-67, was observed in the mice fed with B. lactis. Indeed, colonic inflammation induces strong epithelial erosion due to uncontrolled apoptosis. This increased level of apoptosis, which contributes significantly to the IBD pathology, is presumably due in part to a strong increase of inflammatory cytokines such as TNF and IFN-γ as observed in our study; cytokines known to be able to induce apoptosis directly by suppressing anti-apoptotic signals in the epithelium[43,44]. Hence, since in our experimental setting mice were sacrificed at a late time point relative to onset of inflammation, reparative proliferation was the more relevant parameter to be investigated here rather than apoptosis.
The role of pro-inflammatory cytokines in IBD pathology has been firmly established. Dysregulation of the intestinal immune system both at humoral and cellular level constitutes an important element in the multifactorial pathogenesis of IBD. A strongly elevated expression of pro-inflammatory mediators, most notably IL-6 and TNF-α, has been identified in IBD patients and experimental models of colitis in mice. In cases of acute inflammation, IL-6 synthesized mainly by macrophages first binds to the IL-6 receptor (IL-6R); this complex then associates with gp130, inducing dimerization and the initiation of signaling through STAT-3. In the present study, the decrease of colonic IL-6 expression and STAT-3 phosphorylation induced by B. lactis strongly suggest that the probiotic could act, at least in part, on the IL-6 trans-signaling pathway and could by this process dampen the inflammation. Indeed, previous studies performed in both animal models and humans clearly described that abrogation of IL-6 pathway activation was associated with an improvement of colonic inflammation[47-49].
Moreover, analysis of p38 phosphorylation has confirmed the beneficial impact of B. lactis feeding on inflammation. Indeed, p38 kinase regulates the production of key inflammatory mediators, including TNF-α or IL-1β. In addition, p38 also acts downstream of cytokines such as TNF-α, mediating some of their effects. Hence, the significant diminution of p38 phosphorylation observed in this study upon B. lactis feeding (Figure 4) revealed the broad range of potential effects of the probiotic treatment on colitis.
B. lactis feeding also modulated COX-2 protein expression in the colon of mice (Figure 3C). COX-2, an enzyme responsible for formation of important biological mediators called prostanoids (including prostaglandins, prostacyclin and thromboxane), has been shown to be specifically induced in epithelial cells under IBD conditions. Among the prostanoids related to COX-2 activity, prostaglandins represent one of the most important components of mucosal defence in the small intestine and colon. The weight of evidence collected so far suggests that prostaglandins derived from COX-2 are important in promoting the healing of mucosal injury, in protecting against bacterial invasion, and in down-regulating the mucosal immune system. Suppression of COX-2 in a setting of gastrointestinal inflammation and ulceration has been shown in experimental models to result in impaired healing and exacerbation of inflammation-mediated injury[52-55]. Hence, at the intestinal level, expression of COX-2 is a natural response of the organism to prevent tissue damage due to inflammation and is sustained by this inflammation. In this way, COX-2 expression represents a good marker of the actual disease activity. In the present study, the observed attenuated COX-2 expression upon B. lactis feeding strongly indicates an anti-inflammatory effect of this probiotic bacterium.
Colitis, in the T-cell adoptive transfer model, is accompanied by the accumulation of dendritic cells (DCs) in the MLN as well as locally in the colon. DCs in the MLN express an activated phenotype with increased expression of CD40 and the TNF-like molecule OX40L. Indeed, activated T cells express the cell-surface costimulatory molecules CD40L and OX40. CD40L binds to CD40 on antigen-presenting cells (APCs) inducing OX40L expression, and leading to the transmission of further activatory signals to both the T cell and the APC[59,60]. The CD40-CD40L and OX40L-OX40 pathways play functional roles in the inflammatory response in this model, as blockade of either pathway inhibits colitis[58,61,62]. The overall decrease in these four costimulatory partners observed upon B. lactis feeding (Figure 5) thus revealed a diminished activity of the immune system in sustaining the adaptive inflammatory reactions. The diminution in the number of T cells present in the colonic mucosa of B. lactis-treated mice compared to control animals, as revealed by the measurement of the relative expression of CD3γ mRNA (Figure 6B), might be considered as a partial consequence of this dampening of the costimulatory activity.
Beyond the intensity of the DC-T cell interaction, B. lactis feeding could interfere with the outcome of the interaction in the mucosa. Indeed, B. lactis was also able to significantly decrease T-bet and IFN-γ mRNA expression compared to untreated animals (Figure 6A and C). IFN-γ is the hallmark Th1 cytokine and T-bet is a critical factor for both the initiation and perpetuation of Th1-mediated colitis. Indeed, in another type of adoptive transfer model, T-bet-deficient CD4+CD62L+ T cells failed to induce Th1-mediated colitis in immunodeficient hosts, whereas T-bet-overexpressing CD4+CD62L+ T cells induced a more rapid onset of colitis. The observed diminution of the IFN-γ mRNA expression is fully in line with the decrease of T-bet, revealing a functional impact on activated T cells by B. lactis.
Development of colitis following transfer of CD4+CD45RBhigh T cells into immunodeficient recipients can be modulated or even abrogated by cotransfer of cells from the antigen-experienced CD4+CD45RBlow population, a potential source of Tregs. In the present study, as a small proportion of such cells have been actually cotransferred, we performed a quantification of mRNA expression for Foxp3 in colon samples of recipient mice. This marker has been identified as being necessary for both the development and function of Tregs[64-66]. It appeared that B. lactis feeding significantly potentiated the presence of these particular cells in the inflamed mucosa as treated mice showed a strong augmentation of Foxp3 mRNA expression compared to control mice (Figure 6D) whereas total number of T cells decreased in a converse fashion (Figure 6B). Moreover, while the dampened expression of all analyzed T cell-related proinflammatory markers might be a direct consequence of the diminution in T cell number in the colonic mucosa of B. lactis-fed animals, the fact that Foxp3 mRNA expression was up-regulated indicates a strongly increased prevalence of Tregs in the inflamed tissues. This increase of Treg cells may be one of the key players in the alleviation of the colitis observed in this study.
Despite the fact that mechanisms of action remain unclear, two different options could be hypothesized to explain the effect of probiotics on the Tregs. The classical one will be that probiotics in the colon generated antigenic peptides or molecules able to inhibit or modulate DC activation responsible for uncontrolled T cell proliferation which leads to colitis development, as supported by the diminished expression of the CD40-CD40L and OX40L-OX40 costimulatory partners. More recently, a new hypothesis could be proposed to explain the probiotic effect, involving the toll-like receptor (TLR) pathway. Indeed, it has been revealed that TLR molecules that recognize a vast range of microbial products, thought to be only restricted to cells of innate immunity, are also expressed by Tregs. Interestingly, a recent study demonstrated a role of the TLR2 pathway in the control of expansion and function of Tregs. Such a direct effect of TLR ligands on Tregs thus opens a new way to consider the impact of probiotics in the regulation of colitis. Future investigations on the impact of B. lactis on Tregs will provide interesting pieces of information regarding how and when probiotics exert their effect, as the present study does not allow discrimination as to whether Tregs are potentiated already in donor mice or only in recipient mice upon induction of inflammation.
In conclusion, it was shown in the present study that B. lactis is a Bifidobacterium probiotic strain able to provide anti-inflammatory properties in an adoptive cell transfer model of IBD. Mechanisms of actions are not completely elucidated and need further investigations, but a clear effect on Tregs may be suggested as a key influence.
Ulcerative colitis and Crohn’s disease, commonly known as inflammatory bowel disease (IBD), affect 0.5%-1% of the Western world’s population and are increasing in the developing countries. IBD is a chronic disease that requires lifelong treatment. Many patients do not respond or do not comply well with the recent medications. This, in addition to the high cost of these approaches, urges the scientific community to develop new therapeutic approaches.
Many probiotics have been identified as a powerful strategy to reduce intestinal inflammation in preclinical and human trials. However, despite a high number of publications there are very few explanations concerning their mechanism of action.
Innovations and breakthroughs
Using one of the most valuable murine models of colitis, we have highlighted the fact that a single Bifidobacterium probiotic strain was able to prevent intestinal inflammation by increasing the number of regulatory T cells in the gut.
Through this publication we would like to emphasize that Bifidobactrium lactis (NCC 2818) could be considered as a good auxiliary to current treatment used to reduce intestinal inflammation in IBD patients.
According to the World Health Organization definition, probiotics are live micro-organisms which when consumed in adequate amounts confer health benefits to the host.
In the manuscript, the authors evaluated the anti-inflammatory properties of a B. lactis strain in a colitis mouse model. The experiments were carefully designed and the manuscript is easy to read.
Peer reviewer: Kristin A Verbeke, Professor, Katholieke Universiteit Leuven, Pathophysiology, Section Gastroenterology, University Hospital Gasthuisberg, E462, Herestraat 49, Leuven, 3000, Belgium
S- Editor Sun H L- Editor Logan S E- Editor Lin YP
Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease.Nat Rev Immunol. 2003;3:521-533.
Yu QT, Saruta M, Avanesyan A, Fleshner PR, Banham AH, Papadakis KA. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis.Inflamm Bowel Dis. 2007;13:191-199.
MacDonald TT. Effector and regulatory lymphoid cells and cytokines in mucosal sites.Curr Top Microbiol Immunol. 1999;236:113-135.
Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease.Curr Opin Immunol. 1999;11:648-656.
Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics.Scand J Gastroenterol Suppl. 2001;29-40.
Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation.Annu Rev Immunol. 2002;20:495-549.
Bamias G, Marini M, Moskaluk CA, Odashima M, Ross WG, Rivera-Nieves J, Cominelli F. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease.J Immunol. 2002;169:5308-5314.
Kennedy RJ, Kirk SJ, Gardiner KR. Promotion of a favorable gut flora in inflammatory bowel disease.JPEN J Parenter Enteral Nutr. 2000;24:189-195.
Blum S, Schiffrin EJ. Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria?Curr Issues Intest Microbiol. 2003;4:53-60.
Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.Gastroenterology. 2003;124:1202-1209.
Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.Gastroenterology. 2000;119:305-309.
Sheil B, Shanahan F, O'Mahony L. Probiotic effects on inflammatory bowel disease.J Nutr. 2007;137:819S-824S.
Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.Am J Gastroenterol. 2005;100:1539-1546.
Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.Gut. 2004;53:108-114.
Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, Vitolo D, Boirivant M. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells.Inflamm Bowel Dis. 2008;14:662-668.
Ulisse S, Gionchetti P, D'Alò S, Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment.Am J Gastroenterol. 2001;96:2691-2699.
Imaoka A, Shima T, Kato K, Mizuno S, Uehara T, Matsumoto S, Setoyama H, Hara T, Umesaki Y. Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells.World J Gastroenterol. 2008;14:2511-2516.
Kim N, Kunisawa J, Kweon MN, Eog Ji G, Kiyono H. Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4(+) CD45RB(high) T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation.Clin Immunol. 2007;123:30-39.
Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, Tomiyasu N, Suzuki A, Sata M. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells.Clin Exp Immunol. 2005;140:417-426.
Peran L, Camuesco D, Comalada M, Bailon E, Henriksson A, Xaus J, Zarzuelo A, Galvez J. A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis.J Appl Microbiol. 2007;103:836-844.
Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells.J Exp Med. 1993;178:237-244.
Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.Cell. 1992;68:855-867.
Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice.Int Immunol. 1993;5:1461-1471.
Asseman C, Fowler S, Powrie F. Control of experimental inflammatory bowel disease by regulatory T cells.Am J Respir Crit Care Med. 2000;162:S185-S189.
Shinkai Y, Koyasu S, Nakayama K, Murphy KM, Loh DY, Reinherz EL, Alt FW. Restoration of T cell development in RAG-2-deficient mice by functional TCR transgenes.Science. 1993;259:822-825.
Dewhirst FE, Chien CC, Paster BJ, Ericson RL, Orcutt RP, Schauer DB, Fox JG. Phylogeny of the defined murine microbiota: altered Schaedler flora.Appl Environ Microbiol. 1999;65:3287-3292.
Corazza N, Eichenberger S, Eugster HP, Mueller C. Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells.J Exp Med. 1999;190:1479-1492.
Mudter J, Amoussina L, Schenk M, Yu J, Brüstle A, Weigmann B, Atreya R, Wirtz S, Becker C, Hoffman A. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6.J Clin Invest. 2008;118:2415-2426.
Niess JH, Leithäuser F, Adler G, Reimann J. Commensal gut flora drives the expansion of proinflammatory CD4 T cells in the colonic lamina propria under normal and inflammatory conditions.J Immunol. 2008;180:559-568.
MacDonald TT. Epithelial proliferation in response to gastrointestinal inflammation.Ann N Y Acad Sci. 1992;664:202-209.
Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion.J Exp Med. 1996;183:693-698.
Higgins LM, McDonald SA, Whittle N, Crockett N, Shields JG, MacDonald TT. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein.J Immunol. 1999;162:486-493.
Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats.J Clin Invest. 1996;98:945-953.
Schultz M, Tonkonogy SL, Sellon RK, Veltkamp C, Godfrey VL, Kwon J, Grenther WB, Balish E, Horak I, Sartor RB. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation.Am J Physiol. 1999;276:G1461-G1472.
Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice.Infect Immun. 1998;66:5224-5231.
Herías MV, Koninkx JF, Vos JG, Huis in't Veld JH, van Dijk JE. Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice.Int J Food Microbiol. 2005;103:143-155.
Pavan S, Desreumaux P, Mercenier A. Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria.Clin Diagn Lab Immunol. 2003;10:696-701.
McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.Gut. 2003;52:975-980.
Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M, Price VH, Grisham MB. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade.Am J Physiol Gastrointest Liver Physiol. 2009;296:G135-G146.
Strauch UG, Obermeier F, Grunwald N, Gürster S, Dunger N, Schultz M, Griese DP, Mähler M, Schölmerich J, Rath HC. Influence of intestinal bacteria on induction of regulatory T cells: lessons from a transfer model of colitis.Gut. 2005;54:1546-1552.
Edelblum KL, Yan F, Yamaoka T, Polk DB. Regulation of apoptosis during homeostasis and disease in the intestinal epithelium.Inflamm Bowel Dis. 2006;12:413-424.
Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.Gastroenterol Clin North Am. 1995;24:475-507.
Koshiji M, Adachi Y, Sogo S, Taketani S, Oyaizu N, Than S, Inaba M, Phawa S, Hioki K, Ikehara S. Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression.Clin Exp Immunol. 1998;111:211-218.
Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease.Annu Rev Med. 2000;51:289-298.
Mudter J, Neurath MF. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance.Inflamm Bowel Dis. 2007;13:1016-1023.
Mitsuyama K, Matsumoto S, Masuda J, Yamasakii H, Kuwaki K, Takedatsu H, Sata M. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.Anticancer Res. 2007;27:3749-3756.
Mitsuyama K, Matsumoto S, Rose-John S, Suzuki A, Hara T, Tomiyasu N, Handa K, Tsuruta O, Funabashi H, Scheller J. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice.Gut. 2006;55:1263-1269.
Mitsuyama K, Sata M, Rose-John S. Interleukin-6 trans-signaling in inflammatory bowel disease.Cytokine Growth Factor Rev. 2006;17:451-461.
Schieven GL. The biology of p38 kinase: a central role in inflammation.Curr Top Med Chem. 2005;5:921-928.
Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.Gastroenterology. 1998;115:297-306.
Wallace JL. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation.ScientificWorldJournal. 2006;6:577-588.
Tsubouchi R, Hayashi S, Aoi Y, Nishio H, Terashima S, Kato S, Takeuchi K. Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats.Digestion. 2006;74:91-100.
Süleyman H, Demircan B, Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors.Pharmacol Rep. 2007;59:247-258.
Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.BMC Cancer. 2005;5:46.
Hendel J, Nielsen OH. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease.Am J Gastroenterol. 1997;92:1170-1173.
Karlis J, Penttila I, Tran TB, Jones B, Nobbs S, Zola H, Flesch IE. Characterization of colonic and mesenteric lymph node dendritic cell subpopulations in a murine adoptive transfer model of inflammatory bowel disease.Inflamm Bowel Dis. 2004;10:834-847.
Malmström V, Shipton D, Singh B, Al-Shamkhani A, Puklavec MJ, Barclay AN, Powrie F. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice.J Immunol. 2001;166:6972-6981.
Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. Expression and function of OX40 ligand on human dendritic cells.J Immunol. 1997;159:3838-3848.
Brocker T, Gulbranson-Judge A, Flynn S, Riedinger M, Raykundalia C, Lane P. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles.Eur J Immunol. 1999;29:1610-1616.
De Jong YP, Comiskey M, Kalled SL, Mizoguchi E, Flavell RA, Bhan AK, Terhorst C. Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration.Gastroenterology. 2000;119:715-723.
Liu Z, Geboes K, Colpaert S, Overbergh L, Mathieu C, Heremans H, de Boer M, Boon L, D'Haens G, Rutgeerts P. Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions.J Immunol. 2000;164:6005-6014.
Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Mudter J, Galle PR. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease.J Exp Med. 2002;195:1129-1143.
Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells.Nat Immunol. 2003;4:337-342.
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.Nat Immunol. 2003;4:330-336.
Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3.Science. 2003;299:1057-1061.
Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide.J Exp Med. 2003;197:403-411.
Sutmuller RP, den Brok MH, Kramer M, Bennink EJ, Toonen LW, Kullberg BJ, Joosten LA, Akira S, Netea MG, Adema GJ. Toll-like receptor 2 controls expansion and function of regulatory T cells.J Clin Invest. 2006;116:485-494.